Natco just can’t kick its high-risk, high-gain game plan
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
3 October, 2024•12 min
0
3 October, 2024•12 min
0
More in Business
Business
Is a revival underway at Asian Paints?
The company’s Q2 results show a belated revival in fortunes, suggesting an aggressive growth path in an industry shaken up by Grasim. The latter is feeling the pressure for the first time ever since it launched its paints business in 2024.
You may also like
Business
Dr. Reddy’s wants to be India’s fifth largest drugmaker. What will it take?
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
Health
Indian pharma exporters protesting against new regulations is not a good look
The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.
Internet
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.